Combination therapy targeting cancer metabolism

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 169-172

  Wenger, Justin B ^a   Chun, Sang Y ^b   Dang, Duyen T ^b   Luesch, Hendrik ^a,c   Dang, Long H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL METABOLISM; CITRIC ACID CYCLE; ELECTRON TRANSPORT; ENERGY YIELD; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; ONCOGENE C MYC; ONCOGENE RAS; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROMOLECULAR SUBSTANCES; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 78651091812     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.09.008     Document Type: Article

References (47)

1. Garber K. Energy deregulation: licensing tumors to grow. Science 2006, 312:1158-1159.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Boekema E.J., Braun H.P. Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem 2007, 282:1-4.
4. Hosler J.P., Ferguson-Miller S., Mills D.A. Energy transduction: proton transfer through the respiratory complexes. Annu Rev Biochem 2006, 75:165-187.
5. Duchen M.R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004, 25:365-451.
6. Hervouet E., Simonnet H., Godinot C. Mitochondria and reactive oxygen species in renal cancer. Biochimie 2007, 89:1080-1088.
7. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
8. Pedersen P.L. Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the " Warburg Effect" , i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007, 39:211-222.
9. Bui T., Thompson C.B. Cancer's sweet tooth. Cancer Cell 2006, 9:419-420.
10. Gillies R.J., Gatenby R.A. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr 2007, 39:251-257.
11. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007, 19:223-229.
12. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
13. Tong X., Zhao F., Thompson C.B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 2009, 19:32-37.
14. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
15. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
16. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Nat Acad Sci USA 1997, 94:4273-4278.
17. Tian H., McKnight S.L., Endothelial Russell.D.W., AS P. Domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997, 11:72-82.
18. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. P42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999, 274:32631-32637.
19. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000, 60:1541-1545.
20. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000, 14:391-396.
21. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
22. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Nat Acad Sci USA 2000, 97:10430-10435.
23. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindauprotein. Nat Cell Biol 2000, 2:423-427.
24. D'Angelo G., Duplan E., Boyer N., Vigne P., Frelin C. Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 2003, 278:38183-38187.
25. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003, 23:9361-9374.
26. Chen J., Zhao S., Nakada K., Kuge Y., Tamaki N., Okada F., et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003, 162:1283-1291.
27. Agrawal A., Guttapalli A., Narayan S., Albert T.J., Shapiro I.M., Risbud M.V. Normoxic stabilization of HIF-1alpha drives glycolytic metabolism and regulates aggrecan gene expression in nucleus pulposus cells of the rat intervertebral disk. Am J Physiol Cell Physiol 2007, 293:C621-C631.
28. Dang D.T., Chen F., Gardner L.B., Cummins J.M., Rago C., Bunz F., et al. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006, 66:1684-1696.
29. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
30. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-197.
31. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122.
32. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
33. Samper E., Morgado L., Estrada J.C., Bernad A., Hubbard A., Cadenas S., et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radical Biol Med 2009, 46:387-396.
34. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
35. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Nat Acad Sci USA 2005, 102:5992-5997.
36. Gonzalvez F., Gottlieb E. Cardiolipin: setting the beat of apoptosis. Apoptosis 2007, 12:877-885.
37. Kagan V.E., Tyurin V.A., Jiang J., Tyurina Y.Y., Ritov V.B., Amoscato A.A., et al. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 2005, 1:223-232.
38. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindauprotein. Cancer Cell 2002, 1:237-246.
39. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2:803-811.
40. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Topoisomerase Melillo.G., et al. Mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64:1475-1482.
41. Liu H., Dinkova-Kostova A.T., Talalay P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Nat Acad Sci USA 2008, 105:15926-15931.
42. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004, 10:549-557.
43. Valle I., Alvarez-Barrientos A., Arza E., Lamas S., Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 2005, 66:562-573.
44. Dang D.T., Chen F., Kohli M., Rago C., Cummins J.M., Glutathione Dang.L.H., et al. Transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005, 65:9485-9494.
45. Hokaiwado N., Takeshita F., Naiki-Ito A., Asamoto M., Ochiya T., Shirai T. Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis 2008, 29:1134-1138.
46. Neumann C.A., Cao J., Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 2009, 8:4072-4078.
47. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591.